Table 4 Univariate analysis and multivariate analysis to evaluate the influencing factors of local recurrence

Tumor size

 ≥ 4 cm vs < 4 cm

254 vs. 58

0.036

0–128.503

0.227

0–4,490,352.617

LVSI

Yes vs. No

122 vs. 190

2.082

0.466–9.304

0.655

0.053–8.046

Stromal invasion

Deep 1/3 vs. superficial 1/3 and middle 1/3

28 vs. 284

4.106

0.796–21.164

114.79

2.821–4670.111

Lymph nodes metastasis

Yes vs. No

33 vs. 279

6.459

1.445–28.859

22.706

0.863–597.154

FIGO stage(2009)

IB2-IIA2 vs. IB1

86 vs. 226

0.383

0.046–3.178

0.006

0–3.457

Surgery type

LRH vs. ARH

197 vs. 115

2.33

0.512–10.602

Pre-operative infection status

HPV-16/18 vs. Negative

227 vs. 46

0.844

0.051–13.96

Other 13 Types vs. Negative

39 vs.. 46

0.856

0.097–7.529

Pre-operative HPV-DNA level

Low viral load vs. Negative

192 vs. 46

0.474

0.042–5.34

High viral load vs. Negative

74 vs. 46

2.571

0.278–23.749

Post-operative clearance time (Initial HPV positive)

N = 266

Cleared (within 12 m) vs. Pre- and Post-operative Negative

209 vs. 38

0.177

0.011–2.893

Cleared (12–24 m) vs. Pre- and Post-operative Negative

21 vs. 38

0

0–

Cleared (after 24 m) vs. Pre- and Post-operative Negative

4 vs. 38

0

0–

Uncleared vs. Pre- and Post-operative Negative

32 vs. 38

6.852

0.756–62.061

Post-operative HPV-DNA level

Low level vs. Persistent negative

59 vs. 224

0

0–

0

0–

High level (< 12 m) vs. Persistent negative

11 vs. 224

55.5

8.831–348.792

269.044

14.437–5013.754

High level (12-24 m) vs. Persistent negative

8 vs. 224

13.875

1.137–169.359

31.299

1.191–822.215

High level (> 24 m) vs. Persistent negative

10 vs. 224

0

0–

0

0–